• Please log in or register to access this feature.

Original Article

Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation†

  1. Jiansheng Wang MD1,2,
  2. Jeannelyn S. Estrella MD1,†,
  3. Lan Peng MD1,
  4. Asif Rashid MD, PhD1,
  5. Gauri R. Varadhachary MD3,
  6. Hua Wang MD, PhD3,
  7. Jeffrey E. Lee MD4,
  8. Peter W. T. Pisters MD4,
  9. Jean-Nicolas Vauthey MD4,
  10. Matthew H. Katz MD4,
  11. Henry F. Gomez MD4,
  12. Douglas B. Evans MD5,
  13. James L. Abbruzzese MD3,
  14. Jason B. Fleming MD4,
  15. Huamin Wang MD, PhD1,‡,*

Article first published online: 16 DEC 2011

DOI: 10.1002/cncr.26717

Issue

Cancer

Cancer

Volume 118, Issue 15, pages 3801–3811, 1 August 2012

Additional Information

How to Cite

Wang, J., Estrella, J. S., Peng, L., Rashid, A., Varadhachary, G. R., Wang, H., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Katz, M. H., Gomez, H. F., Evans, D. B., Abbruzzese, J. L., Fleming, J. B. and Wang, H. (2012), Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer, 118: 3801–3811. doi: 10.1002/cncr.26717

Author Information

  1. 1

    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Oncological Surgery, First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China

  3. 3

    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

  4. 4

    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

  5. 5

    Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin

  1. †

    The first 2 authors contributed equally to this article.

  2. ‡

    Fax: (713) 563-1848

*Department of Pathology, Unit 085, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

  • †

    The first 2 authors contributed equally to this article.

  • ‡

    Fax: (713) 563-1848

Publication History

  1. Issue published online: 20 JUL 2012
  2. Article first published online: 16 DEC 2011
  3. Manuscript Accepted: 18 OCT 2011
  4. Manuscript Revised: 25 AUG 2011
  5. Manuscript Received: 25 APR 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (640K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Christoph Tinchon, Eva Hubmann, Angelika Pichler, Felix Keil, Martin Pichler, Hans Rabl, Martin Uggowitzer, Kurt Jilek, Gerhard Leitner, Thomas Bauernhofer, Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma, Acta Oncologica, 2013, 1

    CrossRef

  2. 2
    Kaitlyn J. Kelly, Emily Winslow, David Kooby, Neha L. Lad, Alexander A. Parikh, Charles R. Scoggins, Syed Ahmad, Robert C. Martin, Shishir K. Maithel, H. J. Kim, Nipun B. Merchant, Clifford S. Cho, Sharon M. Weber, Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?, Journal of Gastrointestinal Surgery, 2013,

    CrossRef

View Full Article (HTML) Get PDF (640K)